• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login

    • Chlamydia Infection Treatment

    ID: MRFR/HC/9108-HCR
    142 Pages
    Kinjoll Dey
    September 2025

    Chlamydia is a common sexually transmitted infection (STI) caused by the bacterium Chlamydia trachomatis. The treatment for chlamydia typically involves antibiotics to clear the infection. Various pharmaceutical companies are involved in the production and development of medications used in the treatment of chlamydia.

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Chlamydia Infection Treatment Market Research Report—Forecast till 2032 Infographic
    Summary Table of Contents Segmentation Infographic

    Top Industry Leaders in the Chlamydia Infection Treatment Market

    Chlamydia Infection Treatment Key CompaniesLatest Chlamydia Infection Treatment Companies Update

    September 2023: Evvy, a vaginal health-focused startup founded by women, raised $14 million to expand its precision health platform for women. Prior to introducing its vaginal health test in 2021, the health technology company expanded its platform to provide end-to-end care in February of this year. Patients are linked to virtual health advisers via the platform in order to enhance their comprehension of the outcomes of vaginal health tests that have been reviewed by physicians and to receive personalized prescription treatment. Evvy intends to incorporate antibiotic resistance and sexually transmitted infections (STIs) testing into its reproductive health test as an additional panel, in conjunction with the infusion of new capital. The prescription of antibiotics for the treatment of sexually transmitted infections (STIs) will be customized to consider the health of the vaginal microbiome with the introduction of the new addition.


    July 2023: Harrow, a prominent pharmaceutical company in the eyecare industry in the United States, declared the finalization of the transfer of the New Drug Application (NDA) for VIGAMOX® (moxifloxacin hydrochloride ophthalmic solution) 0.5% to Harrow. VIGAMOX® is a fluoroquinolone antibiotic eye drop intended to treat bacterial conjunctivitis caused by susceptible strains of organisms. Harrow acquired the U.S. commercial rights to VIGAMOX in January 2023. VIGAMOX is the fourth ophthalmic product approved by the FDA subsequent to that acquisition that has successfully concluded the NDA transfer process and is now available for purchase under the Harrow brand. VIGAMOX is widely recognized, dependable, and trusted by eyecare professionals in the United States for its exceptional safety and efficacy.


    List of Chlamydia Infection Treatment Key companies in the market

    • Merck & Co. Inc. (US)

    • Pfizer Inc (US)

    • GlaxoSmithKline Plc(UK)

    • AstraZeneca (UK)

    • Gilead Sciences Inc. (US)

    • Sanofi(France)

    • TevaPharmaceuticals (Israel)

    • Sun Pharma(India)

    • Eli Lilly and Company (US)

    • Novartis (Switzerland)